Emanuele Valtorta
Overview
Explore the profile of Emanuele Valtorta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
4364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Macagno M, Pessei V, Congiusta N, Lazzari L, Bellomo S, Idrees F, et al.
Diagnostics (Basel)
. 2024 Nov;
14(22).
PMID: 39594133
is responsible for the direct repair of O6-methylguanine lesions induced by alkylating agents, including temozolomide. promoter hypermethylation is a well-established biomarker for temozolomide response in glioblastoma patients, also correlated with...
2.
Zagni M, Marando A, Negrelli M, Lauricella C, Motta V, Paglino G, et al.
Pathologica
. 2024 Jul;
116(3):163-169.
PMID: 38979590
The 5th WHO classification of thoracic tumours includes thoracic SMARCA4-deficient undifferentiated tumour (SMARCA4-UT) among the "other epithelial tumours of the lung" chapter. Herein, we present a case of undifferentiated thoracic...
3.
Marando A, Zagni M, Negrelli M, Valtorta E, Lauricella C, Motta V, et al.
Pathologica
. 2024 Mar;
116(1):13-21.
PMID: 38482671
The WHO Classification of Tumors, Thoracic Tumors, 5th edition, has outlined the use of TTF-1 and ΔNP63/P40 to discriminate between adenocarcinoma and squamous cell carcinoma. In 2015, the first description...
4.
Mauri G, Patelli G, Roazzi L, Valtorta E, Amatu A, Marrapese G, et al.
J Clin Pathol
. 2024 Feb;
78(3):195-201.
PMID: 38350716
Background: Methylthioadenosine phosphorylase (MTAP) is an essential metabolic enzyme in the purine and methionine salvage pathway. In cancer, gene copy number loss ( loss) confers a selective dependency on the...
5.
Berrino E, Aquilano M, Valtorta E, Amodio V, Germano G, Gusmini M, et al.
Mod Pathol
. 2023 Feb;
36(2):100012.
PMID: 36853785
Mismatch repair (MMR) protein expression in colorectal cancer (CRC) cells is usually homogeneously retained or lost. Rare lesions may show a heterogeneous pattern of MMR protein expression. We evaluated MMR...
6.
Crisafulli G, Sartore-Bianchi A, Lazzari L, Pietrantonio F, Amatu A, Macagno M, et al.
Cancer Discov
. 2022 May;
12(7):1656-1675.
PMID: 35522273
Significance: MMR-proficient mCRCs are unresponsive to immunotherapy. We provide the proof of concept that inactivation of MMR genes can be achieved pharmacologically with TMZ and molecularly monitored in the tissue...
7.
Sartore-Bianchi A, Lonardi S, Martino C, Fenocchio E, Tosi F, Ghezzi S, et al.
ESMO Open
. 2020 Sep;
5(5):e000911.
PMID: 32988996
Background: HER2 is a therapeutic target for metastatic colorectal cancer (mCRC), as demonstrated in the pivotal HERACLES-A (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification) trial with trastuzumab and lapatinib. The...
8.
Tosi F, Sartore-Bianchi A, Lonardi S, Amatu A, Leone F, Ghezzi S, et al.
Clin Colorectal Cancer
. 2020 Sep;
19(4):256-262.e2.
PMID: 32919890
Background: ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab...
9.
Vigliar E, Malapelle U, Bono F, Fusco N, Cortinovis D, Valtorta E, et al.
Biomed Res Int
. 2019 May;
2019:6832909.
PMID: 31111063
An important harmonization effort was produced by the scientific community to standardize both the preanalytical and interpretative phases of programmed death-ligand 1 (PD-L1) immunohistochemical (IHC) testing in non-small-cell lung cancer...
10.
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F, et al.
Oncologist
. 2019 Apr;
24(10):1395-1402.
PMID: 30952821
Background: HER2 amplification is detected in 3% of patients with colorectal cancer (CRC), making tumors in the metastatic setting vulnerable to double pharmacological HER2 blockade. Preclinical findings show that it...